To begin testing the hypothesis that D2R agonists inhibit SCLC growth by reducing tumour angiogenesis, we orthotopically injected luciferase-labelled human DMS-53 SCLC cells into the left thorax of SCID mice (Fig. 1a). Here, DRD2 is linked to neoplasm.